Results published in the Journal of Urology further highlight the high performance of MDxHealth's bladder cancer test and its potential to allow patients to avoid 77% of the costly, invasive and frequently unnecessary cystoscopies that they are currently subject to. In light of the recent €20m fund-raising, the company appears on track for full US launch of the product in early 2017. With recent Q3 results also in line with our forecasts, we reiterate both our OUTPERFORM recommendation and targe ....
10 Nov 2016
All set for launch of bladder cancer test
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
All set for launch of bladder cancer test
MDxHealth S.A. (0O8G:LON) | 0 0 0.3% | Mkt Cap: 168.5m
- Published:
10 Nov 2016 -
Author:
Chris Redhead -
Pages:
4
Results published in the Journal of Urology further highlight the high performance of MDxHealth's bladder cancer test and its potential to allow patients to avoid 77% of the costly, invasive and frequently unnecessary cystoscopies that they are currently subject to. In light of the recent €20m fund-raising, the company appears on track for full US launch of the product in early 2017. With recent Q3 results also in line with our forecasts, we reiterate both our OUTPERFORM recommendation and targe ....